Vol. 2 No. 9 (2022): September
Reimbursement Recommendations

Dostarlimab (Jemperli)

Published September 12, 2022

Key Messages

  • CADTH recommends that Jemperli should not be reimbursed by public drug plans for monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.
  • While evidence from a clinical trial demonstrated that some patients had disease that responded during treatment with Jemperli, without a control group there is uncertainty in how much the observed responses were due to Jemperli treatment rather than chance.
  • There was too much uncertainty in the reviewed evidence to determine how Jemperli compares to other treatments used in Canada.
  • It is unclear whether Jemperli meets the following needs identified by patients: improved tumour response, delayed disease progression, improved quality of life, and fewer side effects.